Telbivudine
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H318796

CAS#: 3424-98-4

Description: Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (Europe) and Tyzeka (United States). Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance. Telbivudine is a synthetic thymidine nucleoside analogue; it is the L-isomer of thymidine.

Chemical Structure

img
Telbivudine
CAS# 3424-98-4
Instruction

Theoretical Analysis

Hodoodo Cat#: H318796
Name: Telbivudine
CAS#: 3424-98-4
Chemical Formula: C10H14N2O5
Exact Mass: 242.09
Molecular Weight: 242.231
Elemental Analysis: C, 49.58; H, 5.83; N, 11.56; O, 33.02

Price and Availability

Size Price Availability Quantity
25mg USD 450
50mg USD 850
100mg USD 1250
Bulk inquiry

Synonym: LDT 600; LD-T600; LDT600; Telbivudine; Tyzeka; Epavudine

IUPAC/Chemical Name: 1-((2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

InChi Key: IQFYYKKMVGJFEH-CSMHCCOUSA-N

InChi Code: InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1

SMILES Code: O=C1NC(C(C)=CN1[C@@H]2C[C@H]([C@H](CO)O2)O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 242.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Wang YH, Wu BQ, Liu H. Continuous venovenous hemodiafiltration for hyperlactatemia caused by telbivudine in a patient with chronic hepatitis B: a case report and update review. J Dig Dis. 2015 Mar;16(3):164-7. doi: 10.1111/1751-2980.12173. Review. PubMed PMID: 25043654.

2: Lu YP, Liang XJ, Xiao XM, Huang SM, Liu ZW, Li J, Hocher B, Chen YP. Telbivudine during the second and third trimester of pregnancy interrupts HBV intrauterine transmission: a systematic review and meta-analysis. Clin Lab. 2014;60(4):571-86. Review. PubMed PMID: 24779291.

3: Jin JL, Hu P, Lu JH, Luo SS, Huang XY, Weng XH, Zhang JM. Lactic acidosis during telbivudine treatment for HBV: a case report and literature review. World J Gastroenterol. 2013 Sep 7;19(33):5575-80. doi: 10.3748/wjg.v19.i33.5575. Review. PubMed PMID: 24023503; PubMed Central PMCID: PMC3761113.

4: Liu H, Wang X, Wan G, Yang Z, Zeng H. Telbivudine versus entecavir for nucleos(t)ide-naive HBeAg-positive chronic hepatitis B: a meta-analysis. Am J Med Sci. 2014 Feb;347(2):131-8. doi: 10.1097/MAJ.0b013e318286878d. Review. PubMed PMID: 23563307.

5: Liu MH, Sheng YJ, Liu JY, Hu HD, Zhang QF, Ren H. Efficacy of telbivudine on interruption of hepatitis B virus vertical transmission: a meta-analysis. Ann Saudi Med. 2013 Mar-Apr;33(2):169-76. doi: 10.5144/0256-4947.2013.169. Review. PubMed PMID: 23563007.

6: Wang GQ, Ding YP, Dong YH. Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients. J Viral Hepat. 2013 Apr;20 Suppl 1:9-17. doi: 10.1111/jvh.12059. Review. PubMed PMID: 23458520.

7: You H, Jia J. Telbivudine treatment in chronic hepatitis B: experience from China. J Viral Hepat. 2013 Apr;20 Suppl 1:3-8. doi: 10.1111/jvh.12058. Review. PubMed PMID: 23458519.

8: Bertino G, Ardiri AM, Calvagno GS, Bertino N, Ruggeri MI, Malaguarnera M, Malaguarnera G, Toro A, Di Carlo I. Telbivudine on-treatment HBsAg loss in naive HBeAg negative chronic hepatitis B: a case report and brief review of the literature. Clin Ter. 2012 Nov;163(6):e429-34. Review. PubMed PMID: 23306758.

9: Su QM, Ye XG. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis. World J Gastroenterol. 2012 Nov 21;18(43):6290-301. doi: 10.3748/wjg.v18.i43.6290. Review. PubMed PMID: 23180951; PubMed Central PMCID: PMC3501779.

10: Deng M, Zhou X, Gao S, Yang SG, Wang B, Chen HZ, Ruan B. The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis. Virol J. 2012 Sep 4;9:185. doi: 10.1186/1743-422X-9-185. Review. PubMed PMID: 22947333; PubMed Central PMCID: PMC3494585.

11: Jiang H, Wang J, Zhao W. Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2013 Jan;32(1):11-8. doi: 10.1007/s10096-012-1723-6. Epub 2012 Aug 17. Review. PubMed PMID: 22898727.

12: Wiens A, Venson R, Correr CJ, Pontarolo R. Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B. Braz J Infect Dis. 2011 May-Jun;15(3):225-30. Review. PubMed PMID: 21670922.

13: McKeage K, Keam SJ. Telbivudine: a review of its use in compensated chronic hepatitis B. Drugs. 2010 Oct 1;70(14):1857-83. doi: 10.2165/11204330-000000000-00000. Review. PubMed PMID: 20836578.

14: Zhao S, Tang L, Fan X, Chen L, Zhou R, Dai X. Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review. Virol J. 2010 Sep 3;7:211. doi: 10.1186/1743-422X-7-211. Review. PubMed PMID: 20815890; PubMed Central PMCID: PMC2939564.

15: Almeida AM, Ribeiro AQ, Pádua CA, Brandão CM, Andrade EI, Cherchiglia ML, Carmo RA, Acurcio Fde A. [The efficacy of adefovir dipivoxil, entecavir and telbivudine for chronic hepatitis B treatment: a systematic review]. Rev Soc Bras Med Trop. 2010 Jul-Aug;43(4):440-51. Review. Portuguese. PubMed PMID: 20802947.

16: Hann HW. Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses. Expert Opin Pharmacother. 2010 Sep;11(13):2243-9. doi: 10.1517/14656566.2010.512437. Review. PubMed PMID: 20698726.

17: But DY, Yuen MF, Fung J, Lai CL. Safety evaluation of telbivudine. Expert Opin Drug Saf. 2010 Sep;9(5):821-9. doi: 10.1517/14740338.2010.507190. Review. PubMed PMID: 20662545.

18: Hartwell D, Jones J, Harris P, Cooper K. Telbivudine for the treatment of chronic hepatitis B infection. Health Technol Assess. 2009 Oct;13 Suppl 3:23-30. doi: 10.3310/hta13suppl3/04. Review. PubMed PMID: 19846025.

19: Lui YY, Chan HL. Treatment of chronic hepatitis B: focus on telbivudine. Expert Rev Anti Infect Ther. 2009 Apr;7(3):259-68. doi: 10.1586/eri.09.6. Review. PubMed PMID: 19344240.

20: Nash K. Telbivudine in the treatment of chronic hepatitis B. Adv Ther. 2009 Feb;26(2):155-69. doi: 10.1007/s12325-009-0004-y. Epub 2009 Feb 18. Review. PubMed PMID: 19225726.